Changing the Past- The Right of a Post-Regulation Acquirer to Challenge a Regulation [PDF]
Drew, Eliezer
core +1 more source
First report on rapid screening of nanomaterial-based antimicrobial agents against β-lactamase resistance using pGLO plasmid transformed HB 101 K-12 [PDF]
core +1 more source
From bench to bedside, boswellic acids in anti-inflammatory therapy - mechanistic insights, bioavailability challenges, and optimization approaches. [PDF]
Peng C +5 more
europepmc +1 more source
Frankincense preparation promotes formation of inflammation-resolving lipid mediators by manipulating lipoxygenases in human innate immune cells. [PDF]
Nischang V +5 more
europepmc +1 more source
3-acetyl-11-keto-<i>β</i>-boswellic acid and chitosan-Ag nanoparticles for synergistic tumor-resident bacteria mediated prostate cancer therapy. [PDF]
Zou B +6 more
europepmc +1 more source
Enhancing 3-acetyl-11-keto-β-boswellic acid skin permeation <i>via</i> nanostructured lipid carriers: integrating quality by design principles for risk estimation and optimization. [PDF]
Priya S +4 more
europepmc +1 more source
3-O-Acetyl-11-Keto-<b>β</b>-Boswellic Acid Suppresses Colitis-Associated Colorectal Cancer by Inhibiting the NF-Kb Signaling Pathway and Remodeling Gut Microbiota. [PDF]
Xu F +12 more
europepmc +1 more source
Network Pharmacology Combined with Proteomics Reveals That 3‑Acetyl-11-keto-β-boswellic Acid Inhibits the Progression of Prostate Cancer by Regulating the IL-17 Signaling Pathway. [PDF]
Zou B +5 more
europepmc +1 more source
3-Acetyl-11-keto-β-boswellic Acid-Based Hybrids Alleviate Acetaminophen-Induced Hepatotoxicity in HepG2 by the Regulation of Inflammatory and Oxidative Stress Pathways: An Integrated Approach. [PDF]
Elgazar AA +3 more
europepmc +1 more source
Editorial: Volume II: anti-inflammatory drug development focusing on immune mediated diseases. [PDF]
Oliveira-Costa JF +3 more
europepmc +1 more source

